Hepatitis C is a major risk factor for the development of hepatocellular carcinoma (HCC), arising typically on a background of liver cirrhosis. Treatment of hepatitis C has been revolutionized by the addition of oral direct-acting antivirals (DAAs) with sustained virological response (SVR) rates above 90%. There is a recent concern under debate about the increased risk of early HCC recurrence in patients with chronic hepatitis C who were treated with direct-acting antivirals. Nonetheless, these reports mostly focused on patients who were cirrhotic and were already treated for HCC. We report 4 cases of treatment naive, chronic hepatitis C patients who were treated with DAAs and rapidly developed infiltrative HCC despite achieving SVR. Moreover, in our scenario, one of the patients appeared clinically non-cirrhotic until he developed HCC.
References
[1]
Singal, A.G., Volk, M.L., Jensen, D., Di Bisceglie, A.M. and Schoenfeld, P.S. (2010) A Sustained Viral Response Is Associated with Reduced Liver-Related Morbidity and Mortality in Patients with Hepatitis C Virus. Clinical Gastroenterology and Hepatology, 8, 280-288.
[2]
Vezali, E., Aghemo, A. and Colombo, M. (2010) A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis. Clinical Therapeutics, 32, 2117-2138. https://doi.org/10.1016/S0149-2918(11)00022-1
[3]
Livingston, S.E., Townshend-Bulson, L.J., Bruden, D.J., Homan, C.E., Gove, J.E., Plotnik, J.N., et al. (2016) Results of Interferon-Based Treatments in Alaska Native and American Indian Population with Chronic Hepatitis C. International Journal of Circumpolar Health, 75, Article ID: 30696. https://doi.org/10.3402/ijch.v75.30696
[4]
Mashitani, T., Yoshiji, H., Yamazaki, M., Ikenaka, Y., Noguchi, R., Ishikawa, M., et al. (2009) Development of Hepatocellular Carcinoma in a Patient 13 Years after Sustained Virological Response to Interferon against Chronic Hepatitis C: A Case Report. Cases Journal, 2, 18. https://doi.org/10.1186/1757-1626-2-18
[5]
Igarashi, G., Endo, T., Sawada, N., Mikami, K., Sato, K., Kudo, D., et al. (2015) Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients 20 Years after Achieving a Sustained Virological Response with Interferon Therapy: A Report of Two Cases. Journal of General and Family Medicine, 16, 199-203. https://doi.org/10.14442/jgfm.16.3_199
[6]
Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M. and Falck-Ytter, Y. (2013) Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Annals of Internal Medicine, 158, 329-337.
[7]
El-Serag, H.B., Kanwal, F., Richardson, P. and Kramer, J. (2016) Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with Hepatitis C Virus Infection. Hepatology, 64, 130-137.
[8]
Forestier, N., Reesink, H.W., Weegink, C.J., McNair, L., Kieffer, T.L., Chu, H.M., et al. (2007) Antiviral Activity of Telaprevir (VX-950) and Peginterferon Alfa-2a in Patients with Hepatitis C. Hepatology, 46, 640-648. https://doi.org/10.1002/hep.21774
[9]
Fried, M.W., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I., et al. (2013) Once-Daily Simeprevir (TMC435) with Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Hepatitis C: The Randomized PILLAR Study. Hepatology, 58, 1918-1929. https://doi.org/10.1002/hep.26641
[10]
American Association for the Study of Liver Diseases and Infectious Diseases Society of America (2016) HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
[11]
European Association for the Study of the Liver (2017) EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology, 66, 153-194.
[12]
World Health Organization (2016) Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection.
[13]
Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. (2016) Unexpected High Rate of Early Tumor Recurrence in Patients with HCV-Related HCC Undergoing Interferon-Free Therapy. Journal of Hepatology, 65, 719-726. https://doi.org/10.1016/j.jhep.2016.04.008
[14]
Nault, J.-C. and Colombo, M. (2016) Hepatocellular Carcinoma Anddirect Acting Antiviral Treatments: Controversy after the Revolution. Journal of Hepatology, 65, 663-665. https://doi.org/10.1016/j.jhep.2016.07.004
[15]
Llovet, J.M. and Villanueva, A. (2016) Liver Cancer: Effect of HCV Clearance with Direct-Acting Antiviral Agents on HCC. Nature Reviews Gastroenterology & Hepatology, 13, 561-562. https://doi.org/10.1038/nrgastro.2016.140
[16]
Serti, E., Chepa-Lotrea, X., Kim, Y.J., Keane, M., Fryzek, N., Liang, T.J., et al. (2015) Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology, 149, 190-200.e2.
[17]
Bruix, J., Gores, G.J. and Mazzaferro, V. (2014) Hepatocellular Carcinoma: Clinical Frontiers and Perspectives. Gut, 63, 844-855. https://doi.org/10.1136/gutjnl-2013-306627
[18]
Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., et al. (2016) Unexpected High Incidence of Hepatocellular Carcinoma in Cirrhotic Patients with Sustained Virologic Response Following Interferon-Free Direct-Acting Antiviral Treatment. Journal of Hepatology, 65, 856-858. https://doi.org/10.1016/j.jhep.2016.06.009
[19]
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. (2016) Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Journal of Hepatology, 65, 727-733. https://doi.org/10.1016/j.jhep.2016.06.015
[20]
Cardoso, H., Vale, A.M., Rodrigues, S., Gonçalves, R., Albuquerque, A., Pereira, P., et al. (2016) High Incidence of Hepatocellular Carcinoma Following Successful Interferon-Free Antiviral Therapy for Hepatitis C Associated Cirrhosis. Journal of Hepatology, 65, 1070-1071. https://doi.org/10.1016/j.jhep.2016.07.027
[21]
Pol, S. (2016) Lack of Evidence of an Effect of Direct-Acting Antivirals on the Recurrence of Hepatocellular Carcinoma: Data from Three ANRS Cohorts. Journal of Hepatology, 65, 734-740. https://doi.org/10.1016/j.jhep.2016.05.045
[22]
Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al. (2016) Outcomes after Successful Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 65, 741-747. https://doi.org/10.1016/j.jhep.2016.06.019
[23]
Kobayashi, M., Suzuki, F., Fujiyama, S., Kawamura, Y., Sezaki, H., Hosaka, T., et al. (2017) Sustained Virologic Response by Direct Antiviral Agents Reduces the Incidence of Hepatocellular Carcinoma in Patients with HCV Infection. Journal of Medical Virology, 89, 476-483. https://doi.org/10.1002/jmv.24663
[24]
Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., et al. (2017) Hepatocellular Carcinoma Recurrence in Patients with Curative Resection or Ablation: Impact of HCV Eradication Does Not Depend on the Use of Interferon. Alimentary Pharmacology & Therapeutics, 45, 160-168. https://doi.org/10.1111/apt.13821
[25]
Romano, A., Capra, F., Piovesan, S., Chemello, L., Cavalletto, L., Anastassopoulos, G., et al. (2016) Incidence and Pattern of “De Novo” Hepatocellular Carcinoma in HCV Patients Treated with Oral DAAs. 67th Meeting of the American Association for the Study of Liver Diseases: Liver Meeting, Boston, 11-15 November 2016.
[26]
Bertolini, E., Bassi, F. and Fornaciari, G. (2013) Development of Hepatocellular Carcinoma in a Non-Cirrhotic, Long-Term Responder to Antiviral Therapy, Chronic Hepatitis C Patient: What Kind of Surveillance? Annals of Gastroenterology, 26, 80-83.
